甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603087 甘李药业

已收盘 05-06 15:00:00

{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":51.83,"timestamp":1714978800000,"preClose":50.04,"halted":0,"volume":14676009,"delay":0,"floatShares":530999999,"shares":594000000,"eps":0.6511,"marketStatus":"已收盘","marketStatusCode":5,"change":1.79,"latestTime":"05-06 15:00:00","open":50.1,"high":52.23,"low":50.1,"amount":752000000,"amplitude":0.0426,"askPrice":51.84,"askSize":605,"bidPrice":51.83,"bidSize":396,"shortable":0,"etf":0,"ttmEps":0.6511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715045400000},"adr":0,"adjPreClose":50.04,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":55.04,"lowLimit":45.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":594161750,"pbRate":2.84,"roa":"--","roe":"0.89%","epsLYR":0.6,"committee":-0.240789,"marketValue":30795000000,"floatMarketCap":27526000000,"peRate":79.60375,"changeRate":0.0358,"turnoverRate":0.0276,"status":0},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2432666734","title":"东北富豪30年风云，二代站上舞台c位","url":"https://stock-news.laohu8.com/highlight/detail?id=2432666734","media":"投资者网","top":-1,"share":"https://www.laohu8.com/m/news/2432666734?lang=zh_cn&edition=full","pubTime":"2024-05-02 07:35","pubTimestamp":1714606533,"startTime":"0","endTime":"0","summary":"不到10年，公司成功敲响上市钟声。双方约定，公司和甘李药业各负责二代、三代产品。通化东宝方面，自2020年“解禁”后，也开始销售三代产品。2021年，胰岛素确定纳入专项集采。甘李药业方面，6款中标的三代胰岛素价格，较首次集采均有小幅涨价。同期，通化东宝全系列胰岛素收入25.58 亿元，其中三代的占比近30%，约7.7亿元；联邦制药的三代产品销售额6.11亿元。2023年底，通化东宝的利拉鲁肽注射液获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050207490087c9086f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050207490087c9086f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431231657","title":"甘李药业(603087)2023年实现扭亏为盈，2024年集采续约有望增厚业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2431231657","media":"兴业证券","top":-1,"share":"https://www.laohu8.com/m/news/2431231657?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:17","pubTimestamp":1714472246,"startTime":"0","endTime":"0","summary":"投资要点集采红利推动国内制剂销量增长迅速，2023年业绩实现扭亏为盈。2023年，公司实现营业收入26.08亿元，同比增长52.31%；实现归母净利润3.4亿元，2022年同期为-4.4亿元；实现扣非归母净利润2.97亿元，2022年同期为-4.74亿元。2024年一季度收入同比持平，关注2024年度集采续约涨价后业绩增厚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043018301387c36c85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043018301387c36c85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431383042","title":"甘李药业4月29日遭北向资金减持97.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431383042","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431383042?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:30","pubTimestamp":1714440626,"startTime":"0","endTime":"0","summary":"4月29日，北向资金减持甘李药业97.03万股。截止当日收盘，沪股通共持有甘李药业590.95万股，占流通股1.11%。沪股通减持金额前五个股分别为国电南瑞、大秦铁路、贵州茅台、中国船舶、江淮汽车。甘李药业近5个交易日上涨13.68%，沪股通累计减持39.91万股；近20个交易日上涨23.38%，沪股通累计减持102.91万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300935198b642945&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300935198b642945&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431586528","title":"甘李药业（603087）股东北京旭特宏达科技有限公司质押1090万股，占总股本1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431586528","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431586528?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:36","pubTimestamp":1714397783,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业4月29日公开信息显示，股东北京旭特宏达科技有限公司向国金证券股份有限公司合计质押1090.0万股，占总股本1.83%。质押详情见下表：截止本公告日，股东甘忠如已累计质押股份6326.0万股，占其持股总数的30.76%，股东北京旭特宏达科技有限公司已累计质押股份1090.0万股，占其持股总数的22.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900032432.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430754792","title":"甘李药业获民生证券买入评级，集采加速三代胰岛素放量，出海打开成长天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2430754792","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430754792?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:44","pubTimestamp":1714131874,"startTime":"0","endTime":"0","summary":"4月26日，甘李药业获民生证券买入评级，近一个月甘李药业获得1份研报关注。根据研报，民生证券预计，甘李药业将实现国内胰岛素快速放量，全球市场也同步开拓，预计公司2024/2025/2026年实现归母净利润7.15/11.79/16.01亿元，同比增长110.2%/64.80%/35.80%。其中，2023年公司实现营业收入为26.08亿元，同比增长52.31%；归母净利润为3.40亿元，较上年同期相比，实现扭亏为盈。公司产品销量翻倍增长，市场占有率大幅提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261944408b570fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261944408b570fdd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430279394","title":"民生证券给予甘李药业推荐评级 2023年年报&2024年一季报点评：集采加速三代胰岛素放量 出海打开成长天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2430279394","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430279394?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:21","pubTimestamp":1714130510,"startTime":"0","endTime":"0","summary":"民生证券04月26日发布研报称，给予甘李药业（603087.SH，最新价：48.77元）推荐评级。评级理由主要包括：1）产品销量迅速增长，2023年实现扭亏为盈；2）集采加速国产替代，公司产品实现快速放量；3）续约加速三代替换二代胰岛素步伐，公司获得采购基础量进一步扩大；4）加强研发投入，降糖产品线持续发力；5）加快走出去步伐，稳步推进国际化进展。风险提示：产能释放不能与集采降价对冲风险；产品研发不及预期风险；市场竞争加剧风险；集采风险；仿制药风险。文章来源：每日经济新闻原标题：民生证券给予甘李药业推荐评级，2023年年报&2024年一季报点评：集采加速三代胰岛素放量，出海打开成长天花板","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262029298b573398&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262029298b573398&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430208792","title":"民生证券：给予甘李药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430208792","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430208792?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:11","pubTimestamp":1714129880,"startTime":"0","endTime":"0","summary":"民生证券股份有限公司王班近期对甘李药业进行研究并发布了研究报告《2023年年报&2024年一季报点评：集采加速三代胰岛素放量，出海打开成长天花板》，本报告对甘李药业给出买入评级，当前股价为48.77元。甘李药业产品销量迅速增长，2023年实现扭亏为盈。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042619123787b363f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042619123787b363f2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430137872","title":"甘李药业(603087)：核心产品高速放量 集采全线提价中标","url":"https://stock-news.laohu8.com/highlight/detail?id=2430137872","media":"国泰君安","top":-1,"share":"https://www.laohu8.com/m/news/2430137872?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:54","pubTimestamp":1714107256,"startTime":"0","endTime":"0","summary":"集采产品全线提价中标，预计带来利润增厚。维持“增持”评级。考虑到公司核心产品迎来提价，调整2024-2025 年EPS 预测为1.19/2.04 元，新增2026 年EPS 预测2.65 元，维持目标价60.03 元，维持增持评级。核心产品高速放量，运营效率显著提升。2023 年公司国内制剂产品销量同比增长66.36%，其中长效胰岛素同比增长32.47%、餐时和预混胰岛素同比增长112.38%，在胰岛素集采执行以来呈现高速增长趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261254198b55948a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261254198b55948a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430218019","title":"胰岛素集采最大赢家？甘李药业2023年扭亏为盈，押注第四代胰岛素","url":"https://stock-news.laohu8.com/highlight/detail?id=2430218019","media":"时代周报","top":-1,"share":"https://www.laohu8.com/m/news/2430218019?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:26","pubTimestamp":1714105578,"startTime":"0","endTime":"0","summary":"甘李药业以低价换取了这场胰岛素迭代之战的胜利。据统计，甘李药业参与申报的6个品种此次中选价格均有所上涨。甘李药业表示，2024年第一季度扣非净利润的减少，是由于研发费用同比增加所致。目前，甘李药业两大重点创新布局是GLP-1RA和第四代胰岛素。甘李药业自主研发的GZR4注射液和GZR101注射液均属于第四代胰岛素。2023年下半年，美国FDA对上述三款胰岛素进行了批准前检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261226308b558404&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261226308b558404&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430529781","title":"2024财报｜胰岛素低价竞争，甘李药业的得与失","url":"https://stock-news.laohu8.com/highlight/detail?id=2430529781","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2430529781?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:17","pubTimestamp":1714101460,"startTime":"0","endTime":"0","summary":"一方面，2022年胰岛素集采落地后，甘李药业当年对相关经销商进行了补偿，导致当期出现了亏损。2022年的低基数下，其2023年业绩增长压力有所降低；另一方面，胰岛素集采后，甘李药业“以价换量”斩获了一定的订单，有力支持了其业绩的增长。2023年，甘李药业的海外市场收入达到3.27亿元，同比增长了131.78%。对于GLP-1药物给胰岛素药物市场所带来的潜在冲击，甘李药业也指出胰岛素仍然是不可替代的药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042611200287b1a72e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042611200287b1a72e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430298938","title":"甘李药业4月25日获北向资金加仓63.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430298938","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430298938?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:30","pubTimestamp":1714095028,"startTime":"0","endTime":"0","summary":"4月25日, 北向资金增持甘李药业63.33万股。截止当日收盘，沪股通共持有甘李药业594.42万股，占流通股1.11%。沪股通增持金额前五个股分别为招商银行、中国平安、紫金矿业、中控技术、中信证券。甘李药业近5个交易日上涨11.34%，沪股通累计增持18.68万股；近20个交易日上涨19.31%，沪股通累计减持103.84万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609333487b13c83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042609333487b13c83&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430726823","title":"甘李药业（603087）2024年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430726823","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430726823?lang=zh_cn&edition=full","pubTime":"2024-04-26 06:06","pubTimestamp":1714082790,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期甘李药业发布2024年一季报。根据财报显示，本报告期中甘李药业营收净利润同比双双增长。截至本报告期末，公司营业总收入5.6亿元，同比上升0.42%，归母净利润9600.43万元，同比上升95.04%。本次财报公布的各项数据指标表现尚佳。重仓甘李药业的前十大基金见下表：持有甘李药业最多的基金为鹏华医药科技股票A，目前规模为25.94亿元，最新净值1.0626，较上一交易日上涨1.85%，近一年下跌14.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600013186.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430247678","title":"甘李药业(603087)3月31日股东户数8.38万户，较上期减少3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430247678","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430247678?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:07","pubTimestamp":1714036067,"startTime":"0","endTime":"0","summary":"证券之星消息，近日甘李药业披露，截至2024年3月31日公司股东户数为8.38万户，较12月31日减少2712.0户，减幅为3.14%。在生物制品行业个股中，甘李药业股东户数高于行业平均水平，截至3月31日，生物制品行业平均股东户数为3.36万户。从股价来看，2023年12月31日至2024年3月31日，甘李药业区间跌幅为23.87%，在此期间股东户数减少2712.0户，减幅为3.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042517122887ae7f0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042517122887ae7f0b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430619424","title":"走出集采阴影后甘李药业业绩反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2430619424","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2430619424?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:43","pubTimestamp":1714031037,"startTime":"0","endTime":"0","summary":"4月24日晚间，甘李药业发布2023年年报及2024年一季报。2023年，甘李药业实现营收26.08亿元，同比增长52.31%；归属于上市公司股东的净利润3.4亿元，同比扭亏为盈。在2021年的胰岛素专项集采中，甘李药业的六款胰岛素产品全数入围，平均降幅65.33%，且在三类组别中位列A1。而在集采前一年，即2021年，甘李药业贡献了上市以来最佳业绩，营收为36.12亿元，净利润为14.53亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251546018b51fc0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251546018b51fc0b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430811842","title":"甘李药业去年营收26.08亿元 年内胰岛素销量超七千万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2430811842","media":"贝壳财经","top":-1,"share":"https://www.laohu8.com/m/news/2430811842?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:55","pubTimestamp":1714006504,"startTime":"0","endTime":"0","summary":"报告期内，公司营业收入为26.08亿元，同比增长52.31%；归母净利润为3.4亿元，实现扭亏为盈。甘李药业为国内胰岛素龙头，2023年，公司国内销售收入为21.82亿元，较上年同期增长51.93%；国际销售收入约3.27亿元，同比增长131.78%。年报显示，2023年，甘李药业胰岛素制剂的销售量为7321.07万支，同比增长71.99%。报告期内，甘李药业销售费用、管理费用均有所下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042508554379232bd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042508554379232bd2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430419991","title":"甘李药业6款产品中标集采量增价涨 走出集采阵痛2023年预盈3.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2430419991","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2430419991?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:32","pubTimestamp":1714005120,"startTime":"0","endTime":"0","summary":"　　胰岛素生产企业甘李药业在胰岛素接续采购中“收获颇丰”。这6款产品是甘李药业的重磅产品，2023年前三季的销售金额为15.82亿元，占公司当期营业收入比例高达82.99%。　　值得一提的是，遭遇集采阵痛，甘李药业2022年的营收降超50%，归母净利润亏损4.4亿元。进入集采后，甘李药业以价换量，2023年快速扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-04-25/doc-inaszaua6998890.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-04-25/doc-inaszaua6998890.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430611624","title":"图解甘李药业一季报：第一季度单季净利润同比增95.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430611624","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430611624?lang=zh_cn&edition=full","pubTime":"2024-04-25 01:38","pubTimestamp":1713980282,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业2024年一季报显示，公司主营收入5.6亿元，同比上升0.42%；归母净利润9600.43万元，同比上升95.04%；扣非净利润1716.93万元，同比下降42.93%；负债率7.49%，投资收益226.53万元，财务费用-2006.54万元，毛利率72.83%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500002305.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429437142","title":"甘李药业最新公告：一季度净利润9600.43万元 同比增长95.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429437142","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429437142?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:00","pubTimestamp":1713960033,"startTime":"0","endTime":"0","summary":"甘李药业公布2024年第一季度报告，报告期实现营业收入5.6亿元，同比增长0.42%；归属于上市公司股东的净利润9600.43万元，同比增长95.04%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042218.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429432170","title":"甘李药业最新公告：2023年净利润3.4亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2429432170","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429432170?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:51","pubTimestamp":1713959483,"startTime":"0","endTime":"0","summary":"甘李药业公布2023年年度报告，报告期实现营业收入26.08亿元，同比增长52.31%；归属于上市公司股东的净利润3.4亿元，同比扭亏为盈。公司拟向全体股东按每10股派发现金股利2元（含税）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400041743.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","stockEarnings":[{"period":"1week","weight":0.045},{"period":"1month","weight":0.1389},{"period":"3month","weight":0.4235},{"period":"6month","weight":0.0654},{"period":"1year","weight":0.394},{"period":"ytd","weight":-0.0156}],"companyName":"甘李药业股份有限公司","boardCode":"AI0027","perCapita":"6353股","boardName":"医药制造业","registeredCapital":"59416万元","compareEarnings":[{"period":"1week","weight":0.0089},{"period":"1month","weight":0.0233},{"period":"3month","weight":0.1259},{"period":"6month","weight":0.0289},{"period":"1year","weight":-0.0581},{"period":"ytd","weight":0.0557}],"survey":"　　甘李药业股份有限公司主要从事重组胰岛素类似物原料药及注射剂的研发、生产和销售。公司主要产品包括重组甘精胰岛素注射液、重组赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液五个胰岛素类似物品种。公司为唯一掌握产业化生产重组胰岛素类似物技术的中国企业，使得我国成为世界上少数能进行重组胰岛素类似物产业化生产的国家之一。","serverTime":1715014052077,"listedPrice":63.32,"stockholders":"83780人(较上一季度减少3.14%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}